Regenxbio (RGNX) Non Operating Income (2015 - 2026)
Regenxbio (RGNX) posted quarterly Non Operating Income of -$9.5 million for Q4 2025, down 5326.92% year-over-year from $182000.0 in Q4 2024, and little changed quarter-over-quarter from -$9.5 million in Q3 2025.
Regenxbio (RGNX) Non Operating Income (2015 - 2026) Analysis & Trends
Regenxbio's Non Operating Income history runs 11 years deep, the most recent figure standing at -$9.5 million for Q4 2025.
- In Q4 2025, Non Operating Income fell 5326.92% year-over-year to -$9.5 million; the TTM figure through Dec 2025 stood at -$32.7 million (down 623.38% YoY), while the FY2025 annual figure was -$32.7 million, down 623.38% from the prior year.
- Non Operating Income for Q4 2025 stood at -$9.5 million, roughly flat from -$9.5 million in the prior quarter.
- The five-year high for Non Operating Income was $3.1 million in Q3 2023, with the low at -$9.5 million in Q3 2025.
- The 5-year median for Non Operating Income is -$3.3 million (2022), against an average of -$2.9 million.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income surged 202.7% in 2024, then sank 5326.92% in 2025.
- Regenxbio's Non Operating Income stood at -$6.2 million in 2021, then jumped by 64.23% to -$2.2 million in 2022, then soared by 139.06% to $862000.0 in 2023, then sank by 78.89% to $182000.0 in 2024, then tumbled by 5326.92% to -$9.5 million in 2025.
- Business Quant data shows RGNX's Non Operating Income at -$9.5 million in Q4 2025, -$9.5 million in Q3 2025, and -$7.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | -6.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.55 Mn |
| Dec 31, 2025 | -9.51 Mn |
| Sep 30, 2025 | -9.53 Mn |
| Jun 30, 2025 | -7.59 Mn |
| Mar 31, 2025 | -6.04 Mn |
| Dec 31, 2024 | 182,000.00 |
| Sep 30, 2024 | 2.48 Mn |
| Jun 30, 2024 | 3.05 Mn |
| Mar 31, 2024 | 533,000.00 |
| Dec 31, 2023 | 862,000.00 |
| Sep 30, 2023 | 3.09 Mn |
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | -519,000.00 |
| Dec 31, 2022 | -2.21 Mn |
| Sep 30, 2022 | -4.44 Mn |
| Jun 30, 2022 | -5.65 Mn |
| Mar 31, 2022 | -5.24 Mn |
| Dec 31, 2021 | -6.17 Mn |
| Sep 30, 2021 | -1.06 Mn |
| Jun 30, 2021 | -5.41 Mn |